Abstract: Systems and methods for learning and managing robot user interfaces are disclosed herein. One embodiment generates, based on input data including information about past interactions of a particular user with a robot and with existing HMIs of the robot, a latent space using one or more encoder neural networks, wherein the latent space is a reduced-dimensionality representation of learned behavior and characteristics of the particular user, and uses the latent space as input to train a decoder neural network associated with (1) a new HMI distinct from the existing HMIs or (2) a particular HMI among the existing HMIs to alter operation of the particular HMI. The trained first decoder neural network is deployed in the robot to control, at least in part, operation of the new HMI or the particular HMI in accordance with the learned behavior and characteristics of the particular user.

Abstract: Methods, systems, and devices for analyzing objective health data and subject-conveyed health information are disclosed for health information reporting, treatment planning, diagnoses, and treatment. According to an aspect, a method can include receiving objective health data of a subject. Further, the method can include receiving a first set of information about the subject's health. The first set of information was conveyed by the subject. The method includes presenting the objective health data to the subject. The method includes receiving, subsequent to presentation of the objective health data to the subject, a second set of information about the subject's health, wherein the second set of information was conveyed by the subject. The method can also include analyzing the objective health data, the first set of information, and the second set of information. Further, the method can include determining a treatment plan, diagnosis, and/or health information based on the analysis.

Abstract: Cyclic aspiration system including an aspiration catheter and a cyclic aspiration source connected in fluid communication thereto, wherein the cyclic aspiration pressure source produces a cyclic aspiration pressure waveform of intermittently cycling intervals of a vacuum pressure below atmospheric pressure and a positive pressure higher than the vacuum pressure. The system further including a non-powered internal structural impediment disposed within the lumen of the aspiration catheter and configured to engage with a clot capturable therein during resulting movement between the clot and the non-powered internal structural impediment while subject to the cyclic aspiration pressure waveform to assist in capture of the clot. The non-powered internal structural impediment may be permanently attached to the aspiration catheter or a separate component or device independently slidable within the lumen of the aspiration catheter.

Abstract: A bioactive filamentary structure includes a sheath coated with a mixture of synthetic bone graft particles and a polymer solution forming a scaffold structure. In forming such a structure, synthetic bone graft particles and a polymer solution are applied around a filamentary structure. A polymer is precipitated from the polymer solution such that the synthetic bone graft particles and the polymer coat the filamentary structure and the polymer is adhered to the synthetic bone graft particles to retain the graft particles.

Abstract: A 3D printed assisted technology for the visually impaired may contain two separate, identical, low-cost, 3D printed models of cross-sectioned neuroanatomical structures. Both of these models may contain identical tactile, topographical sections that emphasize different systems of the brain. One model may contain pressable buttons and programmable audio components that present audio information to the future and correspond to features on the 3D model.

Abstract: The invention relates to heterocyclic substituted urea derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders.